Login to Your Account



Oscient Paying Reliant $78M For Cholesterol Drug In U.S.

By Randall Osborne


Wednesday, July 26, 2006
Oscient Pharmaceuticals Inc. is gaining a piece of the fenofibrate market with its buyout of U.S. rights to the once-daily, cholesterol-lowering drug Antara from Reliant Pharmaceuticals Inc. for $78 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription